Helus Pharma Taps Intra-Cellular Therapies Veteran as CEO Ahead of Key MDD Trial Data
Event summary
- Michael Halstead, former President of Intra-Cellular Therapies, appointed as Helus Pharma CEO effective immediately.
- Halstead led Intra-Cellular’s US$14.6 billion sale to Johnson & Johnson in 2025 and commercialized CAPLYTA® (lumateperone).
- Helus Pharma prepares for topline data readout from APPROACH, its Phase 3 study of HLP003 for MDD, expected in Q4 2026.
- HLP003 has received Breakthrough Therapy Designation from the FDA.
The big picture
Helus Pharma’s appointment of Michael Halstead as CEO underscores its strategic pivot towards commercialization, following the successful late-stage development trajectory at Intra-Cellular. The move comes as the company prepares for pivotal Phase 3 data readouts, positioning it to potentially disrupt the adjunctive treatment landscape for Major Depressive Disorder (MDD). Halstead’s experience in scaling biopharmaceutical enterprises and navigating high-value acquisitions adds a critical layer of operational expertise ahead of Helus Pharma’s potential commercial milestones.
What we're watching
- Execution Risk
- Whether Halstead can replicate his success at Intra-Cellular in guiding Helus Pharma through late-stage clinical development and commercialization.
- Regulatory Dynamics
- The pace at which the FDA will review HLP003 data, given its Breakthrough Therapy Designation status.
- Market Positioning
- How Helus Pharma positions HLP003 against existing treatments for MDD in a competitive landscape.
Related topics